Aspire Biopharma Holdings Inc.
ASBP evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $12.7M
- Lead Asset:
- Instaprin (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ASBP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ASBP
Aspire Biopharma Holdings Inc. (ASBP) is an early-stage biopharmaceutical and supplements company focused on developing and marketing a novel sublingual delivery technology for known drugs, with its lead candidate being high-dose sublingual aspirin, which has not yet received regulatory approval [sec · filed 2026-04-08].
Key risk: No regulatory approvals
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$12.7M
Cash Runway
—
Lead Asset
Instaprin (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Aspire Biopharma Holdings Inc..
Aspire Biopharma Holdings Inc. (ASBP) is an early-stage biopharmaceutical and supplements company focused on developing and marketing a novel sublingual delivery technology for known drugs, with its lead candidate being high-dose sublingual aspirin, which has not yet received regulatory approval [sec · filed 2026-04-08].
- Aspire is an early-stage biopharmaceutical and supplements company that completed a reverse recapitalization on February 17, 2025, changing its name from PowerUp Acquisition Corp. to Aspire Biopharma Holdings, Inc. [sec · filed 2026-04-08]
- The company's business is highly dependent on the success of its lead product candidate, high-dose sublingual aspirin, which has not yet gained regulatory approval and will require significant additional clinical testing [sec · filed 2025-12-03]
- As of 2026-06-30, Aspire reported cash & equivalents of $12.2M, total revenue of $0.1M, net income of -$1.3M, and shareholders' equity of $11.8M [sec]
- The company has developed a working formula for a single-dose sublingual pre-workout supplement and a 'coffee or soda replacement' supplement, with consumer and safety testing conducted in Q2 2025 [sec · filed 2025-12-03]
- Aspire's product candidates are based on novel sublingual delivery technology, and the regulatory approval pathway for such products is unproven, as all previously FDA-approved aspirin products were administered orally rather than sublingually [sec · filed 2025-12-03]
What works
- Aspire has a novel sublingual delivery platform that could differentiate its products from conventional oral formulations, potentially offering faster absorption and improved bioavailability [sec · filed 2026-04-08]
- The company has already developed and tested a sublingual supplement product (caffeine-based) and entered into a manufacturing agreement with Desert Stream, Inc., indicating progress beyond the drug pipeline [sec · filed 2025-12-03]
- Aspire holds a cash position of $12.2M as of 2026-06-30, which provides a runway to fund ongoing development and operations [sec]
What to weigh
- Aspire has no products that have gained regulatory approval, and its lead candidate, high-dose sublingual aspirin, requires significant additional clinical testing before it can seek approval [sec · filed 2025-12-03]
- The regulatory pathway for sublingual aspirin is unproven because all previously FDA-approved aspirin products were administered orally, not sublingually [sec · filed 2025-12-03]
- The company reported minimal revenue ($0.1M) and a net loss of -$1.3M as of 2026-06-30, reflecting its pre-revenue, early-stage status [sec]
- Aspire's business is highly dependent on the success of a single lead product candidate, creating concentration risk if development or commercialization fails [sec · filed 2025-12-03]
From the filings
Quoted directly from source documents.
Aspire has no approved products and its lead candidate requires significant additional clinical testing
“We do not have any products that have gained regulatory approval. Our business and future success depends on our ability to obtain regulatory approval of and then successfully commercialize our lead product candidate, high-dose sublingual aspirin.”
SEC filings · April 8, 2026
The regulatory pathway for sublingual aspirin is unproven
“the development and regulatory approval pathway for such product candidates is unproven (in that all aspirin products previously approved by the FDA were administered orally rather than sublingually)”
SEC filings · December 3, 2025
Aspire completed a reverse recapitalization in February 2025
“On February 17, 2025, the Company completed the Reverse Recapitalization described below and changed its name to Aspire Biopharma Holdings, Inc.”
SEC filings · April 8, 2026
Aspire has developed a sublingual supplement product and conducted testing
“We have manufactured trial runs of this supplement and conducted consumer and safety testing in Q2 2025.”
SEC filings · December 3, 2025
Risks & what to watch (4)›
Key risks
- No regulatory approvals — Aspire has no products that have gained regulatory approval; its lead candidate requires significant additional clinical testing [sec · filed 2025-12-03]
- Unproven regulatory pathway — All previously FDA-approved aspirin products were oral, not sublingual, making the pathway for Aspire's lead candidate unproven [sec · filed 2025-12-03]
- Single-product dependency — Aspire's business is highly dependent on the success of its lead product candidate, high-dose sublingual aspirin [sec · filed 2025-12-03]
- Minimal revenue and net loss — As of 2026-06-30, Aspire reported total revenue of $0.1M and net income of -$1.3M [sec]
What to watch
- Progress of clinical trials and any NDA filing for high-dose sublingual aspirin [sec · filed 2026-04-08]
- Regulatory feedback from the FDA on the novel sublingual delivery pathway for aspirin [sec · filed 2025-12-03]
- Commercial launch and market acceptance of the sublingual supplement products (Buzz Bomb) [sec · filed 2025-12-03]
- Cash runway and burn rate given the $12.2M cash position as of 2026-06-30 and ongoing net losses [sec]
Sources: SEC filings · SEC MD&A · Generated September 30, 2026 · How we verify sources →
Run Aspire Biopharma Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aspire Biopharma Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.15 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$362K
| Holder | Shares | Value |
|---|---|---|
| ubs group ag | 191,499 | $197K |
| morgan stanley | 76,955 | $79K |
| geode capital management, llc | 43,384 | $45K |
| crewe advisors llc | 20,335 | $21K |
| vanguard capital management llc | 7,859 | $8K |
| toronto dominion bank | 5,000 | $5K |
| vanguard fiduciary trust co | 2,856 | $3K |
| tower research capital llc (trc) | 2,174 | $2K |
| citigroup inc | 1,846 | $2K |
| osaic holdings, inc. | 2 | $2 |
Showing top 10 of 13 institutional holders of Aspire Biopharma Holdings Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 17.3%
- Days to cover
- 0.0
- Shares short
- 27,382
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ASBP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aspire Biopharma Holdings Inc.?
Aspire Biopharma Holdings Inc. (ASBP) is an early-stage biopharmaceutical and supplements company focused on developing and marketing a novel sublingual delivery technology for known drugs, with its lead candidate being high-dose sublingual aspirin, which has not yet received regulatory approval [sec · filed 2026-04-08].
What is Aspire Biopharma Holdings Inc.'s lead drug candidate?
Aspire Biopharma Holdings Inc.'s most advanced tracked candidate is Instaprin (Preclinical) for suspected acute myocardial infarction.
Who is the CEO of Aspire Biopharma Holdings Inc.?
Mr. Kraig T. Higginson is the chief executive officer of Aspire Biopharma Holdings Inc. (ASBP).
Where is Aspire Biopharma Holdings Inc. headquartered?
Aspire Biopharma Holdings Inc. (ASBP) is headquartered in Estero, FL, United States.
What therapeutic areas does Aspire Biopharma Holdings Inc. focus on?
Aspire Biopharma Holdings Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.